| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Catalina Pérez-Olives, Rafael Rivas-Santisteban, Jaume Lillo, Gemma Navarro, Rafael Franc. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases. Advances in experimental medicine and biology. vol 1264. 2021-02-03. PMID:33332005. |
recent advances in the potential of cannabinoids for neuroprotection in alzheimer's, parkinson's, and huntington's diseases. |
2021-02-03 |
2023-08-13 |
Not clear |
| Fengmei Wei, Long Zhao, Yuhong Jin. Signaling molecules targeting cannabinoid receptors: Hemopressin and related peptides. Neuropeptides. vol 79. 2020-11-23. PMID:31831183. |
many studies have linked the endocannabinoid system to neuroinflammatory and neurodegenerative disorders such as parkinson's disease, huntington's chorea, alzheimer's disease, and multiple sclerosis. |
2020-11-23 |
2023-08-13 |
Not clear |
| Myuri Ruthirakuhan, Nathan Herrmann, Ana C Andreazza, Nicolaas Paul L G Verhoeff, Damien Gallagher, Sandra E Black, Alex Kiss, Krista L Lanctô. Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation. Journal of geriatric psychiatry and neurology. vol 33. issue 4. 2020-10-16. PMID:31547752. |
the endocannabinoid system has been a target of interest for agitation in alzheimer disease (ad) because of potential behavioral effects and its potential impact on mechanisms implicated in ad such as oxidative stress (os) and neuroinflammation. |
2020-10-16 |
2023-08-13 |
human |
| Jorge Navarro-Dorado, Nuria Villalba, Dolores Prieto, Begoña Brera, Ana M Martín-Moreno, Teresa Tejerina, María L de Ceballo. Vascular Dysfunction in a Transgenic Model of Alzheimer's Disease: Effects of CB1R and CB2R Cannabinoid Agonists. Frontiers in neuroscience. vol 10. 2020-10-01. PMID:27695396. |
vascular dysfunction in a transgenic model of alzheimer's disease: effects of cb1r and cb2r cannabinoid agonists. |
2020-10-01 |
2023-08-13 |
Not clear |
| Sebastian Walther, Michael Halper. Cannabinoids and Dementia: A Review of Clinical and Preclinical Data. Pharmaceuticals (Basel, Switzerland). vol 3. issue 8. 2020-10-01. PMID:27713372. |
we review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: alzheimer's disease (ad), huntington's disease (hd), parkinson's disease (pd) and vascular dementia (vd). |
2020-10-01 |
2023-08-13 |
human |
| Michaela Defrancesco, Alex Hofe. Cannabinoid as Beneficial Replacement Therapy for Psychotropics to Treat Neuropsychiatric Symptoms in Severe Alzheimer's Dementia: A Clinical Case Report. Frontiers in psychiatry. vol 11. 2020-09-28. PMID:32477187. |
cannabinoid as beneficial replacement therapy for psychotropics to treat neuropsychiatric symptoms in severe alzheimer's dementia: a clinical case report. |
2020-09-28 |
2023-08-13 |
Not clear |
| Md Sahab Uddin, Abdullah Al Mamun, Dewan Md Sumsuzzman, Ghulam Md Ashraf, Asma Perveen, Simona G Bungau, Shaker A Mousa, Hesham R El-Seedi, May N Bin-Jumah, Mohamed M Abdel-Dai. Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease. Frontiers in pharmacology. vol 11. 2020-09-28. PMID:32792944. |
emerging promise of cannabinoids for the management of pain and associated neuropathological alterations in alzheimer's disease. |
2020-09-28 |
2023-08-13 |
Not clear |
| Amanda Mueller, Danielle R Fixe. Use of Cannabis for Agitation in Patients With Dementia. The Senior care pharmacist. vol 35. issue 7. 2020-08-31. PMID:32600509. |
studies have reported changes in the endocannabinoid system in the brain of patients with alzheimer's disease (ad), playing a role in the pathophysiology of ad. |
2020-08-31 |
2023-08-13 |
Not clear |
| David Schubert, Devin Kepchia, Zhibin Liang, Richard Dargusch, Joshua Goldberg, Pamela Mahe. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer's Disease. Molecular neurobiology. vol 56. issue 11. 2020-03-12. PMID:31104297. |
efficacy of cannabinoids in a pre-clinical drug-screening platform for alzheimer's disease. |
2020-03-12 |
2023-08-13 |
Not clear |
| Myuri Ruthirakuhan, Krista L Lanctôt, Danielle Vieira, Nathan Herrman. Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis. The Journal of clinical psychiatry. vol 80. issue 2. 2019-12-23. PMID:30753761. |
natural and synthetic cannabinoids for agitation and aggression in alzheimer's disease: a meta-analysis. |
2019-12-23 |
2023-08-13 |
Not clear |
| Myuri Ruthirakuhan, Krista L Lanctôt, Danielle Vieira, Nathan Herrman. Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis. The Journal of clinical psychiatry. vol 80. issue 2. 2019-12-23. PMID:30753761. |
this meta-analysis investigated the efficacy of cannabinoids on agitation and aggression in patients with alzheimer's disease (ad). |
2019-12-23 |
2023-08-13 |
Not clear |
| Juan A Páez, Nuria E Campill. Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases. Current medicinal chemistry. vol 26. issue 18. 2019-12-02. PMID:29484980. |
innovative therapeutic potential of cannabinoid receptors as targets in alzheimer's disease and less well-known diseases. |
2019-12-02 |
2023-08-13 |
Not clear |
| Patricia Del Cerro, Carolina Alquézar, Fernando Bartolomé, Pedro González-Naranjo, Concepción Pérez, Eva Carro, Juan A Páez, Nuria E Campillo, Ángeles Martín-Requer. Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease. CNS drugs. vol 32. issue 6. 2019-08-15. PMID:29736745. |
activation of the cannabinoid type 2 receptor by a novel indazole derivative normalizes the survival pattern of lymphoblasts from patients with late-onset alzheimer's disease. |
2019-08-15 |
2023-08-13 |
Not clear |
| Ana Isabel Fraguas-Sánchez, Ana Isabel Torres-Suáre. Medical Use of Cannabinoids. Drugs. vol 78. issue 16. 2019-07-30. PMID:30374797. |
as a result, it has been reported that changes in endocannabinoid levels may be related to neurological diseases such as parkinson's disease, huntington's disease, alzheimer's disease and multiple sclerosis, as well as anorexia and irritable bowel syndrome. |
2019-07-30 |
2023-08-13 |
Not clear |
| Florian Bleffert, Joachim Granzin, Holger Gohlke, Renu Batra-Safferling, Karl Erich Jaeger, Filip Kovaci. Pseudomonas aeruginosa esterase PA2949, a bacterial homolog of the human membrane esterase ABHD6: expression, purification and crystallization. Acta crystallographica. Section F, Structural biology communications. vol 75. issue Pt 4. 2019-07-25. PMID:30950828. |
the human membrane-bound α/β-hydrolase domain 6 (abhd6) protein modulates endocannabinoid signaling, which controls appetite, pain and learning, as well as being linked to alzheimer's and parkinson's diseases, through the degradation of the key lipid messenger 2-arachidonylglycerol (2-ag). |
2019-07-25 |
2023-08-13 |
human |
| Anne-Caroline Schmöle, Ramona Lundt, Gregor Toporowski, Jan N Hansen, Eva Beins, Annett Halle, Andreas Zimme. Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer's Disease-Like Pathology. Journal of Alzheimer's disease : JAD. vol 64. issue 2. 2019-07-15. PMID:29865078. |
it is widely accepted that the endocannabinoid system (ecs) is a modulator of neuroinflammation associated with neurodegenerative disorders, including alzheimer's disease (ad). |
2019-07-15 |
2023-08-13 |
mouse |
| Noelia Aparicio, M Teresa Grande, Samuel Ruiz de Martín Esteban, Alicia López, Gonzalo Ruiz-Pérez, Mario Amores, Carmen Vázquez, Ana M Martínez-Relimpio, M Ruth Pazos, Benjamin F Cravatt, Rosa M Tolón, Julián Romer. Role of interleukin 1-beta in the inflammatory response in a fatty acid amide hydrolase-knockout mouse model of Alzheimer's disease. Biochemical pharmacology. vol 157. 2019-07-08. PMID:30195729. |
based on previously reported data, in which we described a paradoxical effect of the genetic deletion of the fatty acid amide hydrolase, we here aimed to expand our knowledge on the role of the endocannabinoid system in the context of alzheimer's disease. |
2019-07-08 |
2023-08-13 |
mouse |
| Noelia Aparicio, M Teresa Grande, Samuel Ruiz de Martín Esteban, Alicia López, Gonzalo Ruiz-Pérez, Mario Amores, Carmen Vázquez, Ana M Martínez-Relimpio, M Ruth Pazos, Benjamin F Cravatt, Rosa M Tolón, Julián Romer. Role of interleukin 1-beta in the inflammatory response in a fatty acid amide hydrolase-knockout mouse model of Alzheimer's disease. Biochemical pharmacology. vol 157. 2019-07-08. PMID:30195729. |
we here describe a previously unknown link between the endocannabinoid system and interleukin-1β in the context of alzheimer's disease that open new possibilities for the development of novel therapeutics. |
2019-07-08 |
2023-08-13 |
mouse |
| Alberto Llorente-Ovejero, Iván Manuel, Laura Lombardero, Maria Teresa Giralt, Catherine Ledent, Lydia Giménez-Llort, Rafael Rodríguez-Puerta. Endocannabinoid and Muscarinic Signaling Crosstalk in the 3xTg-AD Mouse Model of Alzheimer's Disease. Journal of Alzheimer's disease : JAD. vol 64. issue 1. 2019-06-26. PMID:29865071. |
endocannabinoid and muscarinic signaling crosstalk in the 3xtg-ad mouse model of alzheimer's disease. |
2019-06-26 |
2023-08-13 |
mouse |
| Alberto Llorente-Ovejero, Iván Manuel, Laura Lombardero, Maria Teresa Giralt, Catherine Ledent, Lydia Giménez-Llort, Rafael Rodríguez-Puerta. Endocannabinoid and Muscarinic Signaling Crosstalk in the 3xTg-AD Mouse Model of Alzheimer's Disease. Journal of Alzheimer's disease : JAD. vol 64. issue 1. 2019-06-26. PMID:29865071. |
the endocannabinoid system, which modulates emotional learning and memory through cb1 receptors, has been found to be deregulated in alzheimer's disease (ad). |
2019-06-26 |
2023-08-13 |
mouse |